Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...

The deal is the basis for Novo Nordisk's strategy to create capacities for the production of drugs for diabetes and obesity Ozempic and Wegovy ... The headquarters is located in Copenhagen (Denmark) ...

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisks (NYSE:NVO) Ozempic for reducing the risk of kidney ...

Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like nausea and diarrhea. But new research confirms that more serious ...

Few drugs have captured public attention like Ozempic; many of us have even taken it. The type 2 diabetes medication, generically known as semaglutide, has received unprecedented attention in the ...

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.

In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond weight loss. Published in the journal Nature Medicine, this new study ...

Ziyad Al-Aly receives funding from U.S. Department of Veterans Affairs. Several years ago, a little-known drug named Ozempic – previously used only to treat diabetes – emerged as a promising ...

One in eight adults in the U.S. has taken Ozempic or another type of GLP-1 drug, surveys show — and now a major new study has revealed a long list of benefits and some little-known risks.

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%. Novo Nordisk said a Phase 1b/2a clinical trial of amycretin ...

Oprah Winfrey said taking weight-loss drugs, like Ozempic and Wegovy, helped her realize the truth about 'thin people.' In 2023, the media mogul, 70, finally admitted to using an undisclosed GLP-1 ...